Oncotarget

Research Papers:

Common polymorphisms in CD44 gene and susceptibility to cancer: a systematic review and meta-analysis of 45 studies

Meng Zhang, Yangyang Wang, Tingting Fang, Yangke Cai, Yue Xu, Cunye Yan, Li Zhang and Chaozhao Liang _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:76021-76035. https://doi.org/10.18632/oncotarget.12580

Metrics: PDF 852 views  |   HTML 1319 views  |   ?  


Abstract

Meng Zhang1,2,*, Yangyang Wang1,*, Tingting Fang1, Yangke Cai3, Yue Xu1,2, Cunye Yan1, Li Zhang1,2, Chaozhao Liang1,2

1Department of Urology, the First Affiliated Hospital of Anhui Medical University, Hefei, China

2Institute of Urology, Anhui Medical University, Hefei, China

3Department of Urology, The Second People’s Hospital of Guangdong Province, Guangzhou, China

*These authors have contributed equally to this work

Correspondence to:

Chaozhao Liang, email: liang_chaozhao@163.com

Li Zhang, email: lzhang_nanomed@163.com

Keywords: CD44, polymorphism, cancer, meta-analysis, systematic review

Received: March 22, 2016    Accepted: August 24, 2016    Published: October 12, 2016

ABSTRACT

CD44 is one of the commonly recognized stem cell markers, which plays a critical role in many cancer related cellular processes. Relationships between CD44 polymorphisms and cancer risk have been widely investigated previously, whereas results derived from these studies were inconclusive and controversial. We conducted present meta-analysis aiming to explore the association between CD44 polymorphisms and cancer risk. We calculated pooled odds ratios (ORs) corresponding with the 95% confidence intervals (CIs) to make the evaluation clear. Embase, Web of Science, PubMed and Cochrane Library databases were retrieved to identify all eligible publications. As a result, a total of 12 publications comprised 25,777 cases and 27,485 controls fulfilled the inclusion criteria. Nevertheless, the pooled analyses suggested that no significant association was uncovered between CD44 (rs10836347, rs11821102, rs13347, rs1425802, rs353639, rs713330 and rs187115) polymorphisms with overall cancer risk. Subsequently, we conducted subgroup analysis for rs13347 polymorphism based on source of control, and we identified a significantly increased cancer risk for the population-based (P-B) group restricted to a recessive model (TT vs. TC+CC: OR = 2.030, 95%CI: 1.163-3.545, PAdjust < 0.001). In conclusion, our meta-analysis demonstrates that CD44 polymorphisms may not represent risk factors for cancer. Future well-designed large-scale case-control studies are warranted to verify our findings.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12580